131 related articles for article (PubMed ID: 9272633)
1. Identification of amidated forms of GLP-1 in rat tissues using a highly sensitive radioimmunoassay.
van Delft J; Uttenthal LO; Hermida OG; Fontela T; Ghiglione M
Regul Pept; 1997 Jun; 70(2-3):191-8. PubMed ID: 9272633
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma.
Pridal L; Ingwersen SH; Larsen FS; Holst JJ; Adelhorst K; Kirk O
J Pharm Biomed Anal; 1995 Jun; 13(7):841-50. PubMed ID: 8562607
[TBL] [Abstract][Full Text] [Related]
3. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose.
van Delft J; Uttenthal O; Koch C; Ghiglione M
Metabolism; 1999 Jan; 48(1):41-6. PubMed ID: 9920143
[TBL] [Abstract][Full Text] [Related]
4. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas.
Mojsov S; Kopczynski MG; Habener JF
J Biol Chem; 1990 May; 265(14):8001-8. PubMed ID: 1692320
[TBL] [Abstract][Full Text] [Related]
5. Distribution and molecular forms of glucagon-like peptide in the dog.
Suda K; Takahashi H; Fukase N; Manaka H; Tominaga M; Sasaki H
Life Sci; 1989; 45(19):1793-8. PubMed ID: 2593768
[TBL] [Abstract][Full Text] [Related]
6. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
Orskov C; Rabenhøj L; Wettergren A; Kofod H; Holst JJ
Diabetes; 1994 Apr; 43(4):535-9. PubMed ID: 8138058
[TBL] [Abstract][Full Text] [Related]
7. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
[TBL] [Abstract][Full Text] [Related]
8. Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.
Uttenthal LO; Ghiglione M; George SK; Bishop AE; Polak JM; Bloom SR
J Clin Endocrinol Metab; 1985 Sep; 61(3):472-9. PubMed ID: 2991321
[TBL] [Abstract][Full Text] [Related]
9. Developmental patterns of glucagon-like peptide-1-(7-36) amide and peptide-YY in rat pancreas and gut.
Kreymann B; Ghatei MA; Domin J; Kanse S; Bloom SR
Endocrinology; 1991 Aug; 129(2):1001-5. PubMed ID: 1677327
[TBL] [Abstract][Full Text] [Related]
10. Production of antisera to des Asn28 Thr29 Homoser27-glucagon; the development of radioimmunoassay for total glucagon-like immunoreactivity in human plasma.
Nishino T; Kodaira T; Shin S; Imagawa K; Yanaihara N; Shima K; Kumahara Y
Endocrinol Jpn; 1981 Aug; 28(4):419-27. PubMed ID: 6897834
[TBL] [Abstract][Full Text] [Related]
11. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies.
Bak MJ; Wewer Albrechtsen NJ; Pedersen J; Knop FK; Vilsbøll T; Jørgensen NB; Hartmann B; Deacon CF; Dragsted LO; Holst JJ
Diabetes Obes Metab; 2014 Nov; 16(11):1155-64. PubMed ID: 25041349
[TBL] [Abstract][Full Text] [Related]
12. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).
Orskov C; Holst JJ
Scand J Clin Lab Invest; 1987 Apr; 47(2):165-74. PubMed ID: 3576119
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
[TBL] [Abstract][Full Text] [Related]
15. Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat.
Kervran A; Blache P; Bataille D
Endocrinology; 1987 Aug; 121(2):704-13. PubMed ID: 3595539
[TBL] [Abstract][Full Text] [Related]
16. Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period.
Padidela R; Patterson M; Sharief N; Ghatei M; Hussain K
Eur J Endocrinol; 2009 Jan; 160(1):53-8. PubMed ID: 18952761
[TBL] [Abstract][Full Text] [Related]
17. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans.
Wettergren A; Pridal L; Wøjdemann M; Holst JJ
Regul Pept; 1998 Oct; 77(1-3):83-7. PubMed ID: 9809800
[TBL] [Abstract][Full Text] [Related]
18. Cellular and sub-cellular localisation of oxyntomodulin-like immunoreactivity in enteroendocrine cells of human, mouse, pig and rat.
Fothergill LJ; Ringuet MT; Sioras E; Hunne B; Fazio Coles TE; Martins PR; Furness JB
Cell Tissue Res; 2019 Feb; 375(2):359-369. PubMed ID: 30259122
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas.
Inoue K; Hisatomi A; Umeda F; Nawata H
Horm Metab Res; 1991 Sep; 23(9):407-9. PubMed ID: 1743611
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.
Suzuki S; Kawai K; Ohashi S; Mukai H; Yamashita K
Endocrinology; 1989 Dec; 125(6):3109-14. PubMed ID: 2684616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
